Today: 27 April 2026
Gold price today: Bullion slips 1% toward $5,000 as U.S. jobs, CPI loom
10 February 2026
2 mins read

Gold price today: Bullion slips 1% toward $5,000 as U.S. jobs, CPI loom

New York, Feb 10, 2026, 13:32 EST — Regular session

  • Spot gold slid 1%, landing at $5,014.19 an ounce. U.S. futures for April slipped 0.8% to $5,037.20.
  • Traders pulled back on positions before U.S. payrolls and inflation numbers, data that could sway the Fed’s rate view.
  • Silver gave up 3.3% following Monday’s jump, with Indian ETF flows still drawing attention.

Gold slipped on Tuesday, giving up ground after a brief two-day rally that took prices above $5,000. By 11:10 a.m. ET, spot gold was 1% lower at $5,014.19 an ounce. April U.S. futures dropped 0.8% to $5,037.20. Silver took a sharper hit, falling 3.3% to $80.60. Platinum dipped 1.1% to $2,099.93, and palladium was down 1.3% at $1,717.33. “We’re seeing a light pullback or consolidation,” said David Meger, director of metals trading at High Ridge Futures. Reuters

Timing counts here. Bullion now hovers right at that $5,000 psychological floor, and with two key U.S. releases up ahead, the question looms: does this pullback hold, or are things about to get a lot choppier?

Gold doesn’t yield interest. If investors see policy rates heading lower, holding the metal suddenly seems less expensive compared to cash or bonds—and even minor changes in interest-rate expectations can jolt prices quickly.

Wednesday, Feb. 11 will see the U.S. January employment report drop at 8:30 a.m., followed by January’s Consumer Price Index on Friday, Feb. 13, also at 8:30 a.m., according to the U.S. Bureau of Labor Statistics calendar.

Economists surveyed by Reuters are looking for nonfarm payrolls to show a 70,000 gain in January, following December’s 50,000 uptick. White House economic adviser Kevin Hassett told CNBC there’s no reason for investors to “panic” if the jobs data falls short of expectations. Reuters

New U.S. numbers out Tuesday fueled more talk of slowing growth behind the recent wave of rate-cut wagers. Retail sales didn’t budge in December—surprising analysts—and Thomas Ryan at Capital Economics noted that “signs of earlier consumer strength may be starting to falter.” Reuters

The dollar’s drop sent ripples through markets Monday, with spot gold jumping 1.9% to $5,056.21 by early afternoon in New York. April futures wrapped up 2% higher at $5,079.40, as the U.S. dollar slipped 0.8% for the day. “The big mover today is the U.S. dollar,” said Bart Melek, global head of commodity strategy at TD Securities. Reuters

Away from the U.S. macro backdrop, demand cues remain in focus for investors—these signals have helped support the market, even when sessions turn soft. ETF flows are now part of that narrative.

Indian investors flooded gold exchange-traded funds in January, driving inflows up to 240.4 billion rupees—more than double what they put in the month before, and just surpassing the amount that went into equity funds, according to industry data. “We saw extreme volatility in the markets in January,” said Venkat Chalasani, chief executive at the Association of Mutual Funds in India. Reuters

Still, gold faces no sure path to $5,000. If payrolls come in above forecasts, or CPI surprises on the upside, bets on rate cuts could get slashed. Higher yields and a firmer dollar usually spell trouble for bullion.

First up: Wednesday’s payrolls. After that, Friday’s CPI. Any surprises could jolt the rate outlook—and you’d probably see it hit the dollar and U.S. yields before gold reacts.

Stock Market Today

  • Structure Therapeutics (GPCR) Valuation Falters Amid Share Price Decline
    April 26, 2026, 10:46 PM EDT. Structure Therapeutics (GPCR) shares dropped to $45.49, marking a 49.21% decline over 90 days despite a strong 91.62% one-year total return. The biotech's price-to-book (P/B) ratio of 2.1x appears undervalued versus peers' average of 31.2x and the US pharmaceuticals sector average of 2.6x, suggesting cautious investor sentiment. This ratio compares market value to book value, often used for early-stage or loss-making companies. GPCR faces risks from ongoing clinical trials for GSBR-1290 and significant net losses of $141.2 million. Analyst forecasts predict 56.5% annual revenue growth, but uncertainties linger. Investors should balance potential gains with risks, monitoring clinical outcomes and funding capabilities amid a volatile healthcare sector.

Latest article

Kratos Defense Stock Slides Again as Drone Maker’s $1 Billion Growth Bet Faces Test

Kratos Defense Stock Slides Again as Drone Maker’s $1 Billion Growth Bet Faces Test

26 April 2026
Kratos Defense shares dropped 6.5% to $61.26, cutting its market value to $10.6 billion as investors questioned the pace of profit from new contracts. The company recently completed the first flight of its Mk1 Firejet drone and won a Space Force contract worth up to $446.8 million. AeroVironment, L3Harris, and Northrop Grumman also declined. Kratos raised $1.17 billion in a February share offering.
Robinhood’s Earnings Week Now Has a Prediction-Market Problem

Robinhood’s Earnings Week Now Has a Prediction-Market Problem

26 April 2026
Wisconsin sued Robinhood and several rivals over sports event contracts, alleging illegal sports betting through prediction markets. The lawsuit comes days before Robinhood reports first-quarter earnings on Tuesday. Robinhood shares closed at $84.71 Friday, down from $91.28 on Monday. The company said its event contracts are federally regulated and it will defend itself.
SoFi Technologies Stock Faces a Big Q1 Earnings Test as Loan Growth Comes Into Focus

SoFi Technologies Stock Faces a Big Q1 Earnings Test as Loan Growth Comes Into Focus

26 April 2026
SoFi will report first-quarter results before markets open April 29, with management projecting about $1.04 billion in adjusted net revenue and adjusted EPS of 12 cents. Shares closed at $18.44 Friday, valuing the company at $23.8 billion. The company recently launched a digital HELOC and formed a Real Estate Advisory Council. Last quarter, loan originations rose 46% to $10.5 billion and fee-based revenue climbed 53%.
Bloom Energy stock turns choppy as SEC filing details Oracle warrant and Brookfield AI financing
Previous Story

Bloom Energy stock turns choppy as SEC filing details Oracle warrant and Brookfield AI financing

DoorDash stock slips as U.S. retail sales stall — earnings next week loom
Next Story

DoorDash stock slips as U.S. retail sales stall — earnings next week loom

Go toTop